Endoscopic Sleeve Gastroplasty (ESG) Significantly Reduces Liver Stiffness and Fat in MASH Patients
Clinician's Perspective:
• The controlled study randomized 40 participants to either Endoscopic Sleeve Gastroplasty (ESG) or a sham (simulated) procedure to isolate the specific impact of the intervention.
• Weight Loss Efficacy: Participants in the ESG group achieved a mean total body weight loss (TBWL) of 9.47%, more than double the 3.91% achieved by the lifestyle-only control group.
• Liver Fat Reduction: Researchers observed a significant decrease in Steatosis (liver fat accumulation) in the ESG group, with a mean reduction of 0.94 points compared to 0.26 in the sham group.
• Structural Improvement: Liver stiffness, measured via vibration-controlled transient elastography (a non-invasive ultrasound-based tool), decreased by 5.63 kPa in the ESG group, while the control group remained nearly stagnant at 0.2 kPa.
• The 10% Threshold: Data revealed that losing more than 10% of total body weight—regardless of the method—resulted in a 70% resolution rate of MASH (liver inflammation and damage).
• Safety Profile: Major adverse events were limited to 10% of the ESG cohort (2 out of 20 participants), involving localized gastric issues that were resolved conservatively within 72 hours.
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), formerly known as NASH, represents an advanced stage of liver disease characterized by inflammation and cellular damage. While lifestyle modification remains the frontline treatment, fewer than 15% of patients typically achieve the 10% weight loss threshold necessary to reverse the disease. This multicenter, double-blind trial investigated whether Endoscopic Sleeve Gastroplasty (ESG)—a procedure where an endoscopic suturing device reduces gastric volume without surgery—could provide a more reliable path to MASH resolution.
The data suggests a clear divergence in metabolic outcomes between the two groups. Over a 72-week period, the ESG group maintained a significant lead in weight reduction and abdominal perimeter (waist circumference) shrinkage. Specifically, the ESG group saw an average waist reduction of 8.67 cm, compared to just 1.06 cm in the sham group. This reduction in Adiposity (body fat percentage and distribution) correlated directly with improved biochemical markers, including a notable decrease in Gamma-Glutamyl Transferase (GGT), an enzyme often elevated in liver dysfunction.
While the study did not find a statistically significant difference between the two groups in the overall NAFLD Activity Score (NAS)—a composite measure of liver inflammation and ballooning—this may be attributed to the small cohort of 40 participants and the unexpectedly high success of the lifestyle intervention in the sham group. However, when the data was stratified by weight loss percentage, the results were definitive: participants who lost more than 10% of their body weight experienced a 70% resolution of MASH without the worsening of Fibrosis (liver scarring).
Furthermore, ESG demonstrated a significant impact on HOMA-IR (a measure of insulin resistance), suggesting that the mechanical restriction of the stomach may trigger broader metabolic shifts. The procedure’s safety was high; while post-operative nausea was common, serious complications such as perigastric hematoma (a collection of blood outside the stomach) occurred in only two patients and did not require surgical intervention. These findings position bariatric endoscopy as a potential second-line therapy for individuals with obesity and MASH who have not reached therapeutic goals through diet and exercise alone.
Evidence Strength: While this trial utilizes the gold-standard sham-controlled randomized design, the small sample size (n=40) and limited diversity in fibrosis stages result in low statistical power for histological secondary endpoints. Final Rating: ★★★☆☆
Source: Read the full study
